RZL-012
RZL-012 is a pharmaceutical drug with 9 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 9 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
9 of 9 finished
0.0%
0 ended early
0
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
RZL-012 for Dercum's Disease Lipomas
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
Clinical Trials (9)
Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
RZL-012 for Dercum's Disease Lipomas
Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events
An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese vs. Non-Chinese Subjects.
An Open-label Study That Will Test a Second Treatment Session of RZL-012.
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks
Efficacy and Safety of RZL-012 on Submental Fat Reduction
Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9